Abbvie manoeuvres to defend Humira to the last
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Forecasts tell a tale of two continents for biosimilars
Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.
M&A: 2017 proves snooze-worthy on the acquisition front
Pharma and biotech takeover activity slumps to a five-year low in 2017.
